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Purpose:Over the past 2 decades the use of thrombolytic therapy in the management of peripheral occlusive diseases, most
notably peripheral arterial occlusion (PAO) and deep venous thrombosis (DVT), has become an accepted and potentially
preferable alternative to surgery. We examined the period when urokinase was in short supply and subsequently
unavailable, to explore potential differences in clinical outcome and economic effect between urokinase and recombinant
tissue plasminogen activator (rt-PA).
Material and methods:Data were obtained from the Premier Perspective Database, a broad clinical database that contains
information on inpatient medical practices and resource use. The study population included all patients hospitalized in
1999 and 2000 with a primary or secondary diagnosis of PAO or DVT. Incidence was calculated for common adverse
events, including bleeding complications, intracranial hemorrhage, amputation, and death. Cost data were also abstracted
from the database, and are expressed as mean  SD.
Results: Demographic variables were similar in the urokinase and rt-PA groups. The rate of bleeding complications was
similar in the urokinase and rt-PA groups. There were no intracranial hemorrhages in the urokinase group, compared
with a rate of 1.5% in the rt-PA PAO group (P  .087) and 1.9% in the rt-PA DVT group (P  .175). The in-hospital
mortality rate was lower in the urokinase-treated PAO subgroup (3.6% vs 8.5%; P  .026), but a similar finding in the
DVT subgroup did not achieve statistical significance (4% vs 9.8%; P  .069). While pharmacy costs were greater in the
urokinase-treated group ($5472  $5579 vs $3644  $6009, P < .001; PAO subgroup, $11,070  $15,409 vs $6150
 $12,398, P .003), overall hospital costs did not differ significantly between the 2 groups. This finding appears to be
explained by a shorter hospital stay and reduced room and board costs in the urokinase-treated group.
Conclusion: There were significant differences in outcome in patients with PAO and DVT who received treatment with
urokinase and rt-PA. While pharmacy costs were significantly greater when urokinase was used, reduction in length of
stay accounted for similar total hospital costs compared with rt-PA. These findings must be considered in the context of
the retrospective nature of the analysis and the potential to use dosing regimens that differ from those in this study.
(J Vasc Surg 2004;40:971-7.)Thrombolytic therapy has been used in patients with
peripheral arterial occlusion (PAO) and deep venous
thrombosis (DVT) to recanalize the occluded vascular seg-
ment. While there exist several available thrombolytic
agents, urokinase emerged as the cornerstone thrombolytic
agent for management of acute limb ischemia.1,2 In early
1999 Abbott Laboratories temporarily suspended produc-
tion of Abbokinase to focus on issues raised by the United
States Food and Drug Administration during a 1998 in-
spection of the Abbokinase manufacturing process.3 Its
withdrawal left clinicians with thrombolytic alternatives
with which they were considerably less familiar and for
which dosing regimens and delivery techniques had not
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doi:10.1016/j.jvs.2004.08.023been well established for noncoronary uses.4 Subsequently
physicians have been investigating multiple dosing proto-
cols and various administration methods of alternative
thrombolytic therapies, such as recombinant tissue plas-
minogen activator (rt-PA), in an attempt to find a safe and
effective treatment for their patients.5 The clinical literature
suggests that this investigation with new dosing protocols
remains ongoing and that no standard dosing protocol for
rt-PA has been nationally established.6
This retrospective analysis examined health care re-
source use, outcomes, and costs associated with various
treatments in patients with PAO or DVT between January
1999 and December 2000. Urokinase was unavailable in
the United States during much of the study period. The
objective of the analysis was to compare urokinase with
rt-PA in the management of peripheral occlusive diseases.
In addition, analyses were conducted to determine predic-
tors of length of hospital stay and associated costs.
METHODS
Data for this study were obtained from Premier Per-
spective Comparative Database. Premier is a healthcare
alliance collectively owned by more than 200 independent
hospitals and healthcare systems in the United States. Pre-
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care systems. The Premier database is a widely used source
for severity-specific data, and has been used with a Center
for Medicare and Medicaid Services Hospital Quality In-
centive Demonstration Project.7-9 Data collection was paid
for by Abbott Laboratories, independently collected by
Premier, and independently analyzed by us. Data were
submitted quarterly by 199 participating hospitals. Each
hospital provided service level information by hospitaliza-
tion day, including detailed data on medications dispensed,
such as name, dosage, and unit cost. Other information
collected included patient primary and secondary diag-
noses, primary and secondary procedures, payer, incidence
of complications, length of stay, and cost of care by cost
accounting department.
Inclusion and exclusion criteria. The study popula-
tion included all patients hospitalized between January 1,
1999, and December 31, 2000, with a primary or second-
ary diagnosis of PAO or DVT, using the 3M Health Infor-
mation System All Patient Refined DRG software (3M
APR-DRG).10,11 Patients who were readmitted with the
same principal diagnosis to the same hospital or health
system within 30 days were also included. Patients who
received more than 1 type of thrombolytic during their
hospitalization, while rare, were excluded from study.
Statistical analysis. Patients were categorized accord-
ing to treatment and severity of disease. Patients given
urokinase or rt-PA either solely or before surgery were
categorized into respective urokinase or rt-PA groups. Pa-
tients were also categorized according to severity of illness,
as defined by 3M APR-DRG classification of severity based
on secondary diagnoses, interaction of secondary diag-
noses, age, principal diagnosis, and presence of certain
nonoperative procedures. Within each APR-DRG, patients
were categorized into 4 disease severity levels that explain
resource use (1  mild, 2  moderate, 3  major, 4 
severe).10
Data are separately presented for the PAO group and
theDVT subgroups. Incidence andmeans are presented for
hospital and patient characteristics. Information on hospi-
tal characteristics was obtained from the 1999 American
Hospital Association Annual Survey. Incidence was calcu-
lated for common adverse events, including bleeding com-
plications, intracranial hemorrhage, amputation, and
death. Data were not available to differentiate major and
minor bleeding complications other than intracranial hem-
orrhage. Means were determined for hospital length of stay
and total costs. Length of stay was calculated by summing
the number of days from admission to discharge. The total
hospital costs included room and board, and all services or
medications received during the hospitalization. All ser-
vices were assigned an allocated fixed and variable cost,
which reflected different cost structures based on hospital
size, teaching status, region, and relative wages paid to
employees. The statistical methods used included the 2
test and the Fisher exact test for differences in proportions,
and the t test for differences in means. Data are presented asmean  SD unless otherwise indicated. P values were
considered significant when the 2-sided value was .05.
RESULTS
Hospital characteristics. Overall, 20,275 hospitaliza-
tions from 199 hospitals were identified during the study
period. A total of 7172 patients (35.37%) were identified
with either PAO (n  5717, 28.20%) or DVT (n  1455,
7.18%). Of these patients, 1460 (20.4%) received a throm-
bolytic agent, including urokinas in 289 patients (19.8%)
and rt-PA in 1171 patients (80.2%). Most of these admis-
sions originated from hospitals in the southern (57.6%) and
midwestern (22.3%) regions of the United States. For
hospitalizations identified in the PAO and DVT study
groups, most occurred in nonteaching hospitals (80.6%) in
urban settings (88.2%) with a minimum of 200 beds.
Patient demographic data. Demographic data for
the study population are presented in Table I. There were
no differences in age or gender in the urokinase or rt-PA
treatment groups. There were no significant intragroup
differences in the types of hospitals (teaching or nonteach-
ing) or the location of the hospitals by geographic region.
Patients in the urokinase-treated group were, however,
more often covered by Medicare (PAO subgroup only),
and were more frequently from an urban hospital (DVT
subgroup only). Of importance, severity of illness appeared
higher in the rt-PAtreated DVT subgroup, with a greater
incidence of the higher level APR-DRG categories.
Event rates. Rates for key events associated with PAO
and DVT, and use of thrombolytic agents are presented in
Table II.The mortality rate was significantly lower in the
urokinase-treated group with PAO (3.6% vs 8.5%; P 
.026). Intracranial hemorrhage was not reported in any of
192 patients with PAO who received urokinase, but did
occur in 8 of 529 patients (1.5%) in the rt-PA group, a
difference that did not attain statistical significance (P 
.087). None of the 97 patients with DVT patients who
received urokinase had an intracranial hemorrhage, com-
pared with 12 of 642 patients (1.9%) in the rt-PA group, a
difference not statistically significant (P  .175). There
were no differences in rate of amputation in the urokinase
or rt-PA treatment groups with PAO or DVT. The rate of
readmission within 30 days was significantly higher in the
urokinase-treated group with DVT, occurring in 25 of 97
patients (26%) compared with 104 of 642 patients (16.2%)
who received rt-PA (P  .021).
Resource use and cost. Trends toward shorter length
of stay in the urokinase-treated group did not attain statis-
tical significance. Within the PAO subgroup, mean length
of stay for patients given urokinase was 9.0  9.8 days,
compared with 10.0  25.0 days in the rt-PA group (P 
.433), and within the DVT group, mean length of stay for
patients given urokinase was 11.7  14.4 days, compared
with 14.4  19.6 days in the rt-PA group (P  .107)
(Table III).
Mean total hospital costs are presented in Table IV.
Pharmacy costs were higher in the urokinase-treated PAO
andDVT subgroups (P .001 and P .003, respectively).
kinase
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irrespective of the thrombolytic agent used. This observa-
tion may relate to a relatively shorter length of stay in the
urokinase group, accounting for reduced room and board
expenses (P  .128 and P  .014 in the PAO and DVT
subgroups, respectively).
Length of stay predictors. In the PAO group, longer
length of stay was associated with greater severity of illness,
increased use of low molecular weight heparin (LMWH),
Table I. Demographic and severity of illness characteristic
venous thrombosis, receiving urokinase or rt-PA
PAO
Urokinase
n  192
rt-PA
n  529
n % n
Gender
Male 99 52 272 5
Female 93 48 257 4
APR severity level
1 21 10.9 54 1
2 90 46.9 231 4
3 62 32.2 191 3
4 19 9.9 53
Payer source
Medicare 90 46.9 290 5
Managed care 25 13 56 1
Other 77 40.1 183 3
Type of hospital
Teaching 27 14.1 85 1
Non-teaching 165 85.9 444 8
Location of hospital
Midwest 29 15.1 116 2
South 126 65.6 298 4
North 6 3.1 14
West 31 16.1 101 1
Hospital setting
Urban 462 87.3 176 9
Rural 67 12.7 16
Age (mean  SD) 63  16.0 63.7  15.7
PAO, Peripheral arterial occlusion; DVT, deep venous thrombosis; UK, uro
*Statistically significant.
Table II. Complication rates in patients with peripheralar
urokinase or rt-PA
PAO
UK
n  192
rt-PA
n  529
n % n %
Bleeding 9 4.7 18 3.4
Intracranial hemorrhage 0 8 1.5
Amputation 13 6.8 38 7.2
Mortality 7 3.6 45 8.5
30-day readmission 24 12.5 55 10.4
PAO, Peripheral arterial occlusion; DVT, deep venous thrombosis; UK, uro
*Statistically significant.urban hospitals, hospitals in the southern region, emergentadmissions, and patients with Medicaid. Male sex was asso-
ciated with a shorter length of stay; Medicare insurance was
associated with a longer length of stay. In the DVT group,
longer length of stay was associated with greater severity of
illness, increased use of LMWH, urban and teaching hos-
pitals, and hospitals in the northeast region.
Total cost predictors. In the PAO group, higher
costs were associated with greater severity of illness, use of
both glycoprotein IIb or glycoprotein IIIa inhibitors and
patients with peripheral arterial occlusion and deep
DVT
Urokinase
n  97
rt-PA
n  642
P n % n % P
.973 .277
47 48 293 45.6
50 52 349 54.4
.805 .011*
20 21 124 19.3
44 45 193 30.1
17 18 183 28.5
16 16 142 22.1
.017* .231
26 27 234 36.5
17 18 93 14.5
54 56 315 49.1
.511 .886
23 24 148 23.1
74 76 494 76.9
.106 .601
27 28 153 23.8
56 58 362 56.4
4 4 39 6.1
10 10 88 13.7
.107 .001*
95 98 554 86.3
2 2 88 13.7
.915 51.5  17.5 53.7 18.7 .267
.
occlusion and deep venous thrombosis, receiving
DVT
UK
n  97
rt-PA
n  642
P n % n % P
.422 2 2 13 2 .981
.087 0 12 19.1 .175
.849 1 (1%) 7 1.1 .958
.026* 4 4 63 9.8 .069
.424 25 26 104 16.2 .021*
.s of
%
1.4
8.6
0.2
3.7
6.1
7.4
4.8
0.6
4.6
6.1
3.9
1.9
1.3
2.6
9.1
1.7
8.3terial
kinaseLMWH, urban and teaching hospitals, hospitals in the
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aid, and, specifically in combination with surgery, throm-
bolytic drug use. Older age, hospitals with fewer beds,
hospitals in the mortheast region, and patients with HMO
insurance were predictive of lower costs. Within the DVT
group, higher costs were associated with greater severity of
illness, increased LMWHuse, urban and teaching hospitals,
hospitals in the northeast region, and, specifically relative to
surgery, the use of urokinase. Somewhat of a surprise, older
age was associated with lower costs.
Analysis of the pharmacy cost component of total costs
indicated that the wholesale acquisition cost in 1998 to
treat PAO andDVT combined with urokinase ($2068) and
rt-PA ($1650) differed by approximately $500 per course
of treatment. The costs include wasted drug, which com-
monly occurs when a complete vial is not used. However,
additional costs allocated to the pharmacy department dif-
fered considerably more dramatically. Mean pharmacy cost
for urokinase versus rt-PA was $8000 and $5153, respec-
tively. Mean contribution to total hospital cost of selected
services associated with hospitalization are detailed in Table
IV. For example, in this study, the pharmacy total contri-
bution to hospital costs was 32% for urokinase compared
with 22% for rt-PA. There was inadequate detail in the
database (eg, infusion rate, partial vial use) to explain this
difference in pharmacy cost.
Analysis by severity of illness. A separate analysis was
performed using the 4 APR-DRG categories (Tables V and
VI). While the diminished sample sizes of the subgroup
analysis decreased the power of the analysis, differences
were particularly important in patients with DVT patients,
a group with significant disparities in the frequency of
APR-DRG subgroups.
DISCUSSION
The findings of this analysis indicate that conversion in
clinical practice from urokinase to rt-PA for treating periph-
eral occlusive diseases is not without incident, as evidenced
by differences in the rates of outcome variables such as
mortality, hospital costs, and length of stay. Clearly, the
most appropriate means to assess differences between 2
pharmacologic agents is with performance of blinded, ran-
domized trials. Heretofore, there were only 2 prospective,
randomized studies that compared urokinase with rt-PA.
Table III. Length of hospital stay in patients with
peripheral arterial occlusion and deep venous thrombosis
(DVT), receiving urokinase or rt-PA
Days P
PAO UK 9.0  9.8
rt-PA 10.0  25.0 .433
DVT UK 11.7 14.4
rt-PA 14.4  19.6 .107
PAO, Peripheral arterial occlusion; DVT, deep venous thrombosis; UK,
urokinase.The first study found few differences between the agents,but was underpowered.12 The second study, the Surgery vs
Thrombolysis for Ischemic Lower Extremity trial, again
failed to find significant differences between the urokinase-
treated and rt-PAtreated groups. In contrast, a retrospec-
tive study published in 2002 suggested that rt-PA, while
effective, was associated with excessive bleeding in contrast
to historic experience with urokinase.13 Other large retro-
spective studies have corroborated these findings. In a
retrospective study conducted over 9 years at the Cleveland
Clinic Foundation the clinical course of 653 consecutive
patients treated for lower extremity vascular occlusions
with catheter-directed urokinase or rt-PA was compared.14
The authors concluded that thrombolysis with urokinase
appeared safer with urokinase than with rt-PA, with a lower
incidence of hemorrhagic complications. Bleeding compli-
cations have been reported to be more frequent in patients
given rt-PA compared with those given urokinase, perhaps
because of its more pronounced effect in lowering fibrino-
gen; accumulation of large amounts of fragment X, a high
molecular weight clottable fibrinogen degradation prod-
uct; or its higher fibrin specificity and affinity.15-19
While retrospective reviews of data are limited in
their ability to ascribe causality to seemingly consequen-
tial events, the findings of this analysis underscore the
importance of focusing on underlying issues. Since 1999
the dosage of rt-PA used to treat peripheral occlusive
disease have been lowered, in part because of complica-
tions such as bleeding that were demonstrated as its
clinical use expanded.4 It was impossible to cull dosing
information from the database used in the present study.
Clearly, rt-PA dosage used during the period of this
study were higher than those used today. Similarly,
however, urokinase dosage used today is likely signifi-
cantly lower than that used during the period of study, a
change primarily related to the cost of the agent. Con-
comitant heparin therapy has also changed over the last
few years. Clinicians are now less likely to use therapeutic
heparinization during thrombolytic infusions, a feature
common to both urokinase and rt-PA.5 Thus, while
practice changes including lower thrombolytic and hep-
arin dosing regimens represent an inherent limitation of
the present analysis, this evolution was common to both
of the agents studied. Further, a recent literature review
suggests that the bleeding complications are not dose-
related over the range of dosages used clinically.20 Lower
dosage of rt-PA did not appear to reduce the incidence of
major hemorrhage during thrombolytic therapy; there
was no correlation between the incidence of complica-
tions and rt-PA dosage. This finding, while not intuitive,
is similar to the failure to detect dose-related differences
in the risk for bleeding with recombinant urokinase or
recombinant prourokinase.21,22 Despite these observa-
tions, however, we must caution that the observations of
the present study cannot be directly applied to instances
in which different regimens of administration are used.
During the study urokinase was associated with a
higher acquisition cost than was rt-PA. However, there are
other issues that contribute to potentially distorted cost
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not always lead to higher total hospital cost, and more
expensive drugs may be associated with lower total cost and
length of stay. With the reintroduction of urokinase, com-
pared with higher dosage of infusions of urokinase preva-
lent through 1999, lower dosage and combination therapy
dosing options may come into clinical practice. Thrombo-
lytic therapy with urokinase is clinically superior and cost
effective compared with streptokinase, despite lower acqui-
sition cost of streptokinase.23-25
Retrospective database analyses of the type used in this
evaluation have their limitations. Causality is difficult to
ascribe. In addition, statistical differences in retrospective
reviews are based on the quality of the data entered into and
abstracted from the database. Differences in severity of
illness may not have been completely addressed by the
APR-DRG subgroup analysis performed in the present
Table IV. Resource utilization in patients treated with uro
venous thrombosis
Component
PAO
UK rt-PA
$
% of
Total $
% o
Tot
Pharmacy 5,472 5,579 28.4 3,644  6,009 19
Room & board 4,652  5,434 24.2 5,719  13,352 30
Imaging 1,976 1,692 10.3 2,061  1,906 10
Laboratory 878 1,216 4.6 868  1,449 4
Surgical 2,087 4,027 10.8 1,850  2,288 9
Central supply 1,991 2,562 10.3 2,036  2,623 10
Emergency
department
108  163 0.6 122  158 0
Other 2,074 3,419 10.8 2,534  8,641 13
Total 19,239  16,066 100.0 18,833  31,564 100
*Statistically significant.
Table V. Outcome by severity of illness (APR-DRG levels
urokinase or rt-PA
APR-DRG
Severity No.
Bleeding ICH Mortality
LOn % n % n %
1 UK 21 0 0 0 4.4 
rt-PA 54 1 2 0 0 5.0
P .53 — — .40
2 UK 90 6 7 0 0 6.0 
rt-PA 231 5 2.2 0 1 4 6.2 
P .046* — .532 .59
3 UK 62 3 5 0 3 5 10.5
rt-PA 191 11 5.8 2 1 22 11.5 9.4 
P .783 .419 .126 .33
4 UK 19 0 0 4 21 23.9 
rt-PA 53 1 2 6 12 22 42 34.1
P .547 .126 .111 .35
ICH, Intracranial hemorrhage; LOS, length of stay; UK, urokinase.
*Statistically significant.study. Perhaps the greatest confounder in this evaluation,however, is the timing of the analysis. The window of time
selected for the analysis intended to provide a comparison
of 1998 data, before shortage and suspension of sale of
urokinase in the market and the period in which the prod-
uct was unavailable. Although the intent was in part to
consider the effect of this event, relatively little baseline data
were available to truly characterize the established use of
urokinase before suspension of production. However, the
clinical literature supports the safe and effective use of
urokinase, and validates many of the findings in this analy-
sis.
In summary, we observed significant differences in
outcome in patients with PAO and DVT treated with
urokinase and rt-PA. Mortality was lower in patients with
PAO treated with urokinase. Pharmacy costs were signifi-
cantly greater when urokinase was used, but reduction in
length of stay accounted for similar total hospital costs
se or rt-PA for peripheral arterial occlusion and deep
DVT
UK rt-PA
P $
% of
Total $
% of
Total P
.001* 11,070  15,409 35.7 6,150 12,398 23.9 .003*
.128 5,885 1,152 19.0 9,155 648 35.5 .014*
.586 2,307 2,530 7.4 1,705 1,960 6.6 .027*
.926 1,691 4,567 5.5 1,393 2,155 5.4 .528
.440 2,103 71,114 6.8 1,458 4,503 5.7 .388
.836 2,484 4,354 8.0 2,375 6,872 9.2 .833
.323 70  121 0.2 117  182 0.5 .001*
.308 5,416 20,771 17.5 3,407 7,095 13.2 .347
.822 31,026 51,090 100.0 25,760 41,358 100.0 .335
patients with peripheral arterial occlusion treated with
Amputation
30-Day
readmit
Total hospital
costs ($)
Pharmacy
costs ($)n % n %
0 2 10 12,376  7,188 4,380  6,793
0 5 9 11,994  4,974 2,471  1,790
— .972 .825 .218
0 13 14 14,381  7,957 4,449  4,352
8 3.5 23 10 13,396  7,696 2,968  4,280
.074 .252 .308 .006*
9 15 5 8 21,294  14,553 5,922 4,950
20 10.5 21 11 16,534 10,170 3,283 3,037
.385 .509 .019* .001*
4 21 4 21 43,128  29,339 10,058  8,533
10 18 6 11 57,789 87,777 9,092 14,645
.836 .293 .292 .732kina
f
al
.3 
.4
.9
.6
.8
.8
.6
.5
.0) in
S
2.2
2.8
1
4.2
4.3
9
8.5
7.4
4
19.0
73.3
6compared with rt-PA. These differences between urokinase
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randomized comparative trial is needed to validate the
findings. However, the likelihood of funding for such a
study appears marginal. It is important that the observa-
tions of this retrospective analysis be evaluated in the con-
text of practice changes that have occurred over the last few
years, which include lower dosing regimens for the throm-
bolytic agent and concomitant heparin therapy. With the
relaunching of urokinase, clinicians and formulary decision
makers who represent the clinical, pharmacy, and financial
perspectives are obligated to consider and track not just the
relative differences in drug acquisition cost, but the overall
costs incurred by their hospitals.
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